共 128 条
[11]
Kim SH(2004)Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications Eur Radiol 14 559-578
[12]
Choi D(2005)Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase Magn Reson Med Sci 4 1-9
[13]
Kim SH(1992)Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system Radiology 183 59-64
[14]
Kopp AF(1995)Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging Radiology 195 785-792
[15]
Heuschmid M(2009)Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma AJR Am J Roentgenol 192 1675-1681
[16]
Claussen CD(2009)Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA AJR Am J Roentgenol 193 1053-1060
[17]
Iannaccone R(2010)Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma Radiology 255 459-466
[18]
Laghi A(2003)The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews BMC Med Res Methodol 3 25-35
[19]
Catalano C(2005)The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed J Clin Epidemiol 58 882-893
[20]
Vogl TJ(2012)Differentiation of early hepatocellular carcinoma from benign hepatocellular nodules on gadoxetic acid-enhanced MRI Br J Radiol 67 148-156